Skip to Content

Treatment after JAKi in patients with rheumatoid arthritis

This study, presented by Professor of Medicine and Rheumatology Janet Pope, highlights the effectiveness of cycling JAK inhibitors (JAKi) of different classes compared with switching to a biological disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) after failure to the first JAKi.

Janet Pope

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top